{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:52:56Z","timestamp":1785009176419,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41401-020-0479-2","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T10:03:48Z","timestamp":1596189828000},"page":"641-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1\/2"],"prefix":"10.1038","volume":"42","author":[{"given":"Shu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ping","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-jie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-xing","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-guang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-yi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-bing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-ding","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"479_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ejh.13271","volume":"103","author":"R Dada","year":"2019","unstructured":"Dada R. Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol. 2019;103:152\u201363.","journal-title":"Eur J Haematol"},{"key":"479_CR2","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","volume":"85","author":"AR Martin","year":"1995","unstructured":"Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood. 1995;85:3671\u20138.","journal-title":"Blood"},{"key":"479_CR3","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","volume":"28","author":"T Relander","year":"2010","unstructured":"Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28:2902\u201313.","journal-title":"J Clin Oncol"},{"key":"479_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1600-0609.2008.01050.x","volume":"80","author":"ES Jaffe","year":"2008","unstructured":"Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Eur. J. Haematol. 2008;80:523\u201331.","journal-title":"Eur. J. Haematol"},{"key":"479_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0002-9440(10)63313-5","volume":"165","author":"T Katzenberger","year":"2004","unstructured":"Katzenberger T, Ott G, Klein T, Kalla J, Muller-Hermelink HK, Ott MM. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol. 2004;165:481\u201390.","journal-title":"Am J Pathol"},{"key":"479_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","volume":"96","author":"H Horn","year":"2011","unstructured":"Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96:1327\u201334.","journal-title":"Haematologica"},{"key":"479_CR7","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944\u201352.","journal-title":"Blood"},{"key":"479_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"479_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-018-3578-0","volume":"98","author":"A Huttmann","year":"2019","unstructured":"Huttmann A, Rekowski J, Muller SP, Hertenstein B, Franzius C, Mesters R, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the \u201cPositron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas\u201d (PETAL) trial. Ann Hematol. 2019;98:897\u2013907.","journal-title":"Ann Hematol"},{"key":"479_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/10428194.2013.802778","volume":"55","author":"BE Wahlin","year":"2014","unstructured":"Wahlin BE, Sundstrom C, Sander B, Christensson B, Jeppsson-Ahlberg A, Hjalmarsson E, et al. Higher world health organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leuk Lymphoma. 2014;55:288\u201395.","journal-title":"Leuk Lymphoma"},{"key":"479_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A, Foa R, Gaidano G, Gamba E, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013;5:826\u201337.","journal-title":"MAbs"},{"key":"479_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol. 1998;9:995\u20131001.","journal-title":"Ann Oncol"},{"key":"479_CR13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","volume":"97","author":"U Jager","year":"2012","unstructured":"Jager U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97:1431\u20138.","journal-title":"Haematologica"},{"key":"479_CR14","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","volume":"129","author":"M Tout","year":"2017","unstructured":"Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017;129:2616\u201323.","journal-title":"Blood"},{"key":"479_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3233\/HAB-2010-0215","volume":"19","author":"L Tran","year":"2010","unstructured":"Tran L, Baars JW, Aarden L, Beijnen JH, Huitema AD. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Hum Antib. 2010;19:7\u201313.","journal-title":"Hum Antib"},{"key":"479_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"479_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1124\/dmd.112.050112","volume":"41","author":"M Munekage","year":"2013","unstructured":"Munekage M, Ichikawa K, Kitagawa H, Ishihara K, Uehara H, Watanabe J, et al. Population pharmacokinetic analysis of daikenchuto, a traditional Japanese medicine (Kampo) in Japanese and US health volunteers. Drug Metab Dispos. 2013;41:1256\u201363.","journal-title":"Drug Metab Dispos"},{"key":"479_CR18","doi-asserted-by":"publisher","first-page":"105211","DOI":"10.18632\/oncotarget.22114","volume":"8","author":"L Song","year":"2017","unstructured":"Song L, He CY, Yin NG, Liu F, Jia YT, Liu Y. A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants. Oncotarget. 2017;8:105211\u201321.","journal-title":"Oncotarget"},{"key":"479_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","volume":"81","author":"M Candelaria","year":"2018","unstructured":"Candelaria M, Gonzalez D, Fernandez Gomez FJ, Paravisini A, Del Campo Garcia A, Perez L, et al. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. Cancer Chemother Pharmacol. 2018;81:515\u201327.","journal-title":"Cancer Chemother Pharm"},{"key":"479_CR20","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","volume":"23","author":"K Brendel","year":"2006","unstructured":"Brendel K, Comets E, Laffont C, Laveille C, Mentre F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharmacol Res. 2006;23:2036\u201349.","journal-title":"Pharmacol Res"},{"key":"479_CR21","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ajodo.2017.04.009","volume":"151","author":"D Koletsi","year":"2017","unstructured":"Koletsi D, Pandis N. Conditional logistic regression. Am J Orthod Dentofac Orthop. 2017;151:1191\u20132.","journal-title":"Am J Orthod Dentofac Orthop"},{"key":"479_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdh176","volume":"15","author":"K Tobinai","year":"2004","unstructured":"Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 2004;15:821\u201330.","journal-title":"Ann Oncol"},{"key":"479_CR23","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","volume":"52","author":"J Li","year":"2012","unstructured":"Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, et al. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012;52:1918\u201326.","journal-title":"J Clin Pharmacol"},{"key":"479_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4049\/jimmunol.1202645","volume":"190","author":"L Bologna","year":"2013","unstructured":"Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol. 2013;190:231\u20139.","journal-title":"J Immunol"},{"key":"479_CR25","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","volume":"186","author":"L Bologna","year":"2011","unstructured":"Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011;186:3762\u20139.","journal-title":"J Immunol"},{"key":"479_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdw026","volume":"27","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, et al. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016;27:895\u2013901.","journal-title":"Ann Oncol"},{"key":"479_CR27","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633\u201359.","journal-title":"Clin Pharmacokinet"},{"key":"479_CR28","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O\u2019Brien","year":"2001","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165\u201370.","journal-title":"J Clin Oncol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0479-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0479-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0479-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:50Z","timestamp":1684616630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0479-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-0479-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}